Telix Pharmaceuticals (TLPPF) Accounts Payables (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Accounts Payables for 4 consecutive years, with $169.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables changed N/A year-over-year to $169.0 million in Q2 2026; TTM through Jun 2026 was $169.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $150.3 million, up 73.23% from the prior year.
• Accounts Payables was $169.0 million for Q2 2026 at Telix Pharmaceuticals, up from $150.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $169.0 million in Q2 2026 and troughed at $53.2 million in Q4 2023.
• A 4-year average of $116.0 million and a median of $120.9 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 72.04% in 2024 and jumped 64.3% in 2025, its largest moves.
• Over 4 years, Accounts Payables stood at $53.2 million in 2023, then soared by 72.04% to $91.5 million in 2024, then jumped by 64.3% to $150.3 million in 2025, then grew by 12.39% to $169.0 million in 2026.
• The last three Accounts Payables figures came in at $169.0 million (Q2 2026), $150.3 million (Q4 2025), and $91.5 million (Q4 2024), per Business Quant data.